MARKET

PRRUF

PRRUF

Immutep Ltd
OTCPK
0.017
NaN%
Opening 09:30 11/18 EST
OPEN
--
PREV CLOSE
0.017
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.334
52 WEEK LOW
0.017
MARKET CAP
24.77M
P/E (TTM)
-0.4504
1D
5D
1M
3M
1Y
5Y
1D
Immutep announces data from its Phase I study of IMP761
TipRanks · 11/09 00:25
Immutep Reports Positive Phase I Data for Autoimmune Candidate IMP761
TipRanks · 11/08 22:13
Immutep to Present Efti Trial Data at Two Oncology Congresses
TipRanks · 11/04 22:21
Immutep Refocuses Efti Development, Elevates IMP761 as Cash Runway Extends to 2028
TipRanks · 10/28 21:37
Immutep Sets Date and Agenda for 2026 Annual General Meeting
TipRanks · 10/27 02:57
Immutep Files Updated Corporate Governance Disclosures for FY2026
TipRanks · 10/27 02:47
Immutep Sets Out Governance and Market Footing in 2026 Annual Report
TipRanks · 10/27 02:37
Immutep Files 2026 Form 20-F, Confirms Accelerated Filer Status
TipRanks · 10/25 21:55
More
About PRRUF
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.

Webull offers Immutep Ltd stock information, including OTCPK: PRRUF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRRUF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRRUF stock methods without spending real money on the virtual paper trading platform.